These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19370758)

  • 21. The DESIRE-Late registry: what is left to be desired?
    Windecker S; Räber L
    JACC Cardiovasc Interv; 2010 Jan; 3(1):19-21. PubMed ID: 20129563
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug-eluting stents for ST-segment elevation myocardial infarction: treatment of choice or is discretion the better part of valor?
    Rihal CS
    JACC Cardiovasc Interv; 2008 Jun; 1(3):233-5. PubMed ID: 19463305
    [No Abstract]   [Full Text] [Related]  

  • 23. Subintimal tracking and re-entry technique with contrast guidance: a safer approach.
    Carlino M; Godino C; Latib A; Moses JW; Colombo A
    Catheter Cardiovasc Interv; 2008 Nov; 72(6):790-6. PubMed ID: 19006242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing the impact of primary percutaneous coronary intervention in acute myocardial infarction.
    Satler LF
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):201. PubMed ID: 21290554
    [No Abstract]   [Full Text] [Related]  

  • 25. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffuse in-stent restenosis of CYPHER® stent due to hypersensitivity reaction confirmed by pathohistological findings.
    Otsuka Y; Nakamura M; Kokubu N; Tonooka A; Inoue K; Higami T
    Heart Vessels; 2012 Jan; 27(1):110-3. PubMed ID: 21526419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
    Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
    JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study.
    Unverdorben M; Vallbracht C; Cremers B; Heuer H; Hengstenberg C; Maikowski C; Werner GS; Antoni D; Kleber FX; Bocksch W; Leschke M; Ackermann H; Boxberger M; Speck U; Degenhardt R; Scheller B
    EuroIntervention; 2015 Dec; 11(8):926-34. PubMed ID: 25169589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bare metal stent thrombosis 13 years after implantation.
    Sarkees ML; Bavry AA; Galla JM; Bhatt DL
    Cardiovasc Revasc Med; 2009; 10(1):58-9. PubMed ID: 19159857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program.
    Turco MA; Ormiston JA; Popma JJ; Hall JJ; Mann T; Cannon LA; Webster MW; Mishkel GJ; O'Shaughnessy CD; McGarry TF; Mandinov L; Dawkins KD; Baim DS
    JACC Cardiovasc Interv; 2008 Dec; 1(6):699-709. PubMed ID: 19463387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of drug-eluting and bare-metal stents for stable coronary artery disease.
    Horst B; Rihal CS; Holmes DR; Bresnahan JF; Prasad A; Gau G; Lennon R; Lerman A
    JACC Cardiovasc Interv; 2009 Apr; 2(4):321-8. PubMed ID: 19463444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
    Brodie BR; Wilson H; Stuckey T; Nussbaum M; Laurent S; Bradshaw B; Humphrey A; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of percutaneous coronary intervention for chronic total occlusions.
    Mehran R; Claessen BE; Godino C; Dangas GD; Obunai K; Kanwal S; Carlino M; Henriques JP; Di Mario C; Kim YH; Park SJ; Stone GW; Leon MB; Moses JW; Colombo A;
    JACC Cardiovasc Interv; 2011 Sep; 4(9):952-61. PubMed ID: 21939934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are we totally clear?
    Morrison DA
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):987-8. PubMed ID: 19953511
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug-eluting stents: more dollars than sense?
    Garg S; Eisenberg MJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1188-9. PubMed ID: 20129544
    [No Abstract]   [Full Text] [Related]  

  • 36. Direct drug-eluting stenting to reduce stent restenosis: a randomized comparison of direct stent implantation to conventional stenting with pre-dilation or provisional stenting in elective PCI patients.
    Remkes WS; Somi S; Roolvink V; Rasoul S; Ottervanger JP; Gosselink AT; Hoorntje JC; Dambrink JH; de Boer MJ; Suryapranata H; van 't Hof AW;
    JACC Cardiovasc Interv; 2014 Jul; 7(7):751-8. PubMed ID: 25060017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial.
    Moreno R; Garcia E; Teles RC; Almeida MS; Carvalho HC; Sabate M; Martin-Reyes R; Rumoroso JR; Galeote G; Goicolea FJ; Moreu J; Mainar V; Mauri J; Ferreira R; Valdes M; Perez de Prado A; Martin-Yuste V; Jimenez-Valero S; Sanchez-Recalde A; Calvo L; Lopez de Sa E; Macaya C; Lopez-Sendon JL
    EuroIntervention; 2010 May; 6(1):112-6. PubMed ID: 20542806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Procedural and one-year clinical outcomes of bioresorbable vascular scaffolds for the treatment of chronic total occlusions: a single-centre experience.
    Özel E; Taştan A; Öztürk A; Özcan EE; Kilicaslan B; Özdogan Ö
    Cardiovasc J Afr; 2016 Nov/Dec 23; 27(6):345-349. PubMed ID: 27078224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repetita iuvant.
    Colombo A
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):468-9. PubMed ID: 18819144
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: a retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial.
    Jeger RV; Brunner-La Rocca HP; Hunziker PR; Tsakiris DA; Kaiser CA; Pfisterer ME;
    Clin Ther; 2009 Dec; 31(12):2886-93. PubMed ID: 20110027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.